Warwick spin-out Medherant has reported positive results from its initial first-stage clinical trial at Hammersmith Medicines Research (HMR); London. The announcement comes as Menopause Awareness Month is celebrated, which focuses us on this major change in women's lives. The technology tested - Medherant's innovative TEPI Patch® - aims to support women through menopause by restoring testosterone to normal pre-menopausal levels.
Founded in 2014, Medherant is developing a new generation of medicinal patch technologies. Following the successful results of the pilot formulation of its testosterone the new optimised TEPI Patch® demonstrated improved testosterone delivery to post-menopausal women, successfully returning blood levels to the normal range seen in pre-menopausal women.
David Haddleton, Chief Scientific Officer at Medherant and Professor in the Department of Chemistry, University of Warwick said: "The success of this initial trial paves the way for our upcoming multiple-dose study which will start dosing before the end of the year. We remain committed to accelerating development to bring the testosterone TEPI Patch to market swiftly and to deliver the adhesion and comfort that women deserve."
Medherant's TEPI Patch is an innovative drug delivery system with a proprietary adhesive that gives the TEPI Patch unprecedented comfort, tolerability and adhesion. The patch is well-tolerated, leaves no residue, and is both flexible and comfortable, allowing women to wear it as they go about their normal lives. This offers a promising option for women seeking to treat a major unmet need in menopause hormone treatment.
The company has received Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee approval of its Clinical Trial Application for its next Phase 1 multiple dose pharmacokinetic study for this product. This is being developed to treat hypoactive sexual desire disorder - distressing low libido - in post-menopausal women.
"These latest results represent another major step in the development of the testosterone TEPI Patch to address a significant condition faced by many post-menopausal women," says Karolina Afors, Medherant's Medical Director. "Our patch technology will provide women with a superior treatment option for testosterone as part of menopause hormone therapy."
